Market Overview

Axovant Sciences Falls 70% After Phase 3 Intepirdine MINDSET Trial Doesn't Meet Endpoint


Axovant Sciences Ltd (NASDAQ: AXON) shares are trading lower by $17.65, or 72 percent, at $6.60 in Tuesday's session.

The catalyst for the sharp decline is the announcement that is Phase 3 Intepirdine MINDSET clinical trial did not meet its co-primary efficacy endpoints. The drug is being tested for use with patients with Alzheimer's disease.

After a much lower open, Axovant attempted to rally but found sellers at $7.40 and resumed its move lower. It went on to breach its opening print of $6.37, but only fell to $6.13 and is attempting to rebound.

Posted-In: Technicals Intraday Update Movers Trading Ideas


Related Articles (AXON)

View Comments and Join the Discussion!
Lightning Fast
Market News Service
$199 Free 14 Day Trial
Book A Demo
Learn How You Can Succeed In The Market With Benzinga Pro

Fastest Market News

Real-Time News Alerts

Customizable News Filters

Book A Demo

Hey Siri, How Positive Is The New Deal With Apple For Google's Ecosystem?

Analyst Tips His Cap To Red Hat After Yet Another Beat And Raise Quarter